SML3972
Azeliragon
≥98% (HPLC)
别名:
PF-04494700, PF04494700, 3-(4-{2-Butyl-1-[4-(4-chlorophenoxy)-phenyl]-1H-imidazole-4-yl}-phenoxy)-propyl]-diethylamine 1, 3-[4-[2-Butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine), PF 04494700, TTP 488, TTP-488, TTP488
登录查看公司和协议定价
所有图片(2)
About This Item
推荐产品
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
, White to light brown
溶解性
DMSO: 2 mg/mL, clear
储存温度
room temp
SMILES字符串
Clc1ccc(cc1)Oc2ccc(cc2)[n]3c(nc(c3)c4ccc(cc4)OCCCN(CC)CC)CCCC
InChI
1S/C32H38ClN3O2/c1-4-7-9-32-34-31(25-10-16-28(17-11-25)37-23-8-22-35(5-2)6-3)24-36(32)27-14-20-30(21-15-27)38-29-18-12-26(33)13-19-29/h10-21,24H,4-9,22-23H2,1-3H3
InChI key
KJNNWYBAOPXVJY-UHFFFAOYSA-N
生化/生理作用
Orally active, brain-penetrant, selective receptor for advanced glycation end products (RAGE) antagonist in vitro and in vivo.
Azeliragon (PF-04494700; TTP488) is an orally active, brain-penetrant, selective receptor for advanced glycation end products (RAGE) antagonist (Kd = 12.7 nM using sRAGE; little affinity toward >100 receptors/transporters) that blocks known RAGE ligands binding (S100b, amphoterin, carboxymethyl-lysine, and Aβ1-42). Azeliragon (0.3-3 mg/kg/day p.o.) reduces brain amyloid (Aβ1-40 & Aβ1-42) and inflammatory markers (TNF-α, TGF-β and IL-1), while increases plasma Aβ in tgAPPSWE/LON mice, a mouse model with Swedish and London mutations that over-express human APP.
Azeliragon (PF-04494700; TTP488) is an orally active, brain-penetrant, selective receptor for advanced glycation end products (RAGE) antagonist (Kd = 12.7 nM using sRAGE; little affinity toward >100 receptors/transporters) that blocks known RAGE ligands binding (S100b, amphoterin, carboxymethyl-lysine, and Aβ1-42). Azeliragon (0.3-3 mg/kg/day p.o.) reduces brain amyloid (Aβ1-40 & Aβ1-42) and inflammatory markers (TNF-α, TGF-β and IL-1), while increases plasma Aβ in tgAPPSWE/LON mice, a mouse model with Swedish and London mutations that over-express human APP.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective
Journal of Medicinal Chemistry, 60(17), 7213-7232 (2017)
Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease
The journal of prevention of Alzheimer's disease, 5(2), 149-154 (2018)
Melinda Magna et al.
NPJ breast cancer, 9(1), 59-59 (2023-07-14)
Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic cancer subtype, which is generally untreatable once it metastasizes. We hypothesized that interfering with the Receptor for Advanced Glycation End-products (RAGE) signaling with the small molecule RAGE inhibitors (TTP488/Azeliragon and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门